Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.The Japanese Ministry of Health, Labour and Welfare (MHLW) has approved Chugai Pharmaceutical's anti-cancer drug Trastuzumab (genetical recombination, brand name: Herceptin Injection 60 and 150), for the additional indication of advanced or recurrent gastric cancer overexpressing HER2, not amenable to curative resection.
Subscribe to our email newsletter
With this approval, Herceptin is now available for patients with HER2-positive advanced or recurrent gastric cancer and HER2-positive breast cancer (advanced or recurrent / postoperative adjuvant chemotherapy) in Japan as well as US and Europe.
Chugai Pharma has submitted the application for the approval with the MHLW in March 2010.
The submission was supported by the results from a Phase III clinical study (ToGA) evaluated patients with inoperable locally advanced, recurrent and/or metastatic HER2-positive gastric cancer.